Professional
Added to YB: 2026-01-22
Pitch date: 2026-01-20
IMRX [neutral]
Immuneering Corporation
-23.37%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Market Cap
$261.4M
Pitch Price
$4.75
Price Target
18.00 (+395%)
Dividend
N/A
EV/EBITDA
-1.32
P/E
-4.12
EV/Sales
N/A
Sector
Biotechnology
Category
value
Show full summary:
ToffCap's Monday Monitor - Immuneering Corporation
IMRX (update): Biotech seeing heavy insider buying on open market despite recent negative trial data, with insiders appearing to view weakness as opportunity. Sell-side analysts maintaining +270% upside price targets, suggesting disconnect between market reaction and fundamental outlook.
Read full article (1 min)